IL1B and gout: A deeper understanding of the mechanisms by which these inflammatory factors exert their effects is crucial for the development of novel therapeutic strategies, such as the use of IL-1β antagonists (e.g., anakinra) to mitigate the symptoms of gout.[6] However, research on the role of other CIPs in gout remains limited.